ADC Therapeutics (NYSE:ADCT – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.15, reports. The company had revenue of $21.72 million for the quarter, compared to the consensus estimate of $18.69 million. During the same quarter last year, the business posted ($0.30) earnings per share.
ADC Therapeutics Stock Down 0.3%
Shares of ADCT stock opened at $1.57 on Monday. The company has a 50 day moving average of $1.36 and a 200-day moving average of $2.43. ADC Therapeutics has a 12-month low of $0.78 and a 12-month high of $4.98. The firm has a market cap of $201.08 million, a P/E ratio of -2.39 and a beta of 1.82.
Wall Street Analyst Weigh In
Several analysts have recently issued reports on the stock. Guggenheim reduced their target price on shares of ADC Therapeutics to $5.00 and set a “buy” rating for the company in a research note on Monday, August 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of ADC Therapeutics in a research report on Thursday, October 15th. Finally, Wall Street Zen upgraded shares of ADC Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $5.00.
View Our Latest Analysis on ADCT
About ADC Therapeutics
ADC Therapeutics SA (NYSE: ADCT) is a biotechnology company focused on developing and commercializing antibody-drug conjugates (ADCs) for the treatment of cancer. Its ADC platform is designed to combine monoclonal antibodies that target specific tumor-associated antigens with potent cytotoxic payloads, with the goal of selectively delivering treatment to cancer cells while limiting exposure to healthy tissue.
The company’s lead product is Zynlonta (loncastuximab tesirine-lpyl), an ADC directed against the CD19 antigen.
See Also
- Five stocks we like better than ADC Therapeutics
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for ADC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
